Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Markers of hepatocellular carcinoma in Hep C-related cirrhosis

Anti-Hep B core antigen-positive results on serologic testing are a marker of hepatocellular carcinoma risk in Hep C virus-related cirrhosis, shows this month's Annals of Internal Medicine.

News image

fiogf49gjkf04

Previous exposure to Hepatitis B virus and occult Hepatitis B virus infection may have an role in hepatocellular carcinoma in patients with chronic liver disease related to Hepatitis C virus.

Dr Kazuki Ikeda and colleagues from Japan prospectively studied the association between antibody to Hepatitis B core antigen and clinical outcomes in patients with Hepatitis C virus-related chronic liver disease.

Hepatocellular carcinoma was diagnosed in 60% with anti-Hep B core antigen
Annals of Internal Medicine

The team assessd 872 patients with chronic Hepatitis C virus infection, of which 597 had chronic Hepatitis, and 275 had cirrhosis.

The research team measured incidence of hepatocellular carcinoma on follow-up from 1995 to 2005.

Only 846 of the 872 enrolled patients were followed up.

The team found that hepatocellular carcinoma occurred in 28% of patients.

Among patients with cirrhosis, hepatocellular carcinoma was diagnosed in 60% with anti-Hepatitis B core antigen.

The researchers noted that hepatocellular carcinoma was diagnosed in 45% without Hepatitis B virus-related serologic markers.

Of 224 patients with chronic hepatitis who had interferon monotherapy, 41% had sustained or transient disappearance of Hepatitis C virus RNA.

None of the anti-Hepatitis B core antigen-negative patients who had a virologic response to interferon therapy developed hepatocellular carcinoma.

The researchers observed that cancer was diagnosed in 4 of 37 anti-Hepatitis B core antigen -positive patients with a virologic response to interferon.

On further analysis, the team found that anti-Hepatitis B core antigen-positive results on serologic testing was an independent risk factor in patients with cirrhosis.

The researchers undertook only 1 assessment of smoking and alcohol consumption at study entry.

The team reported that they did not precisely determine the duration of smoking or alcohol use.

Dr Ikeda's team concluded, " Anti-Hepatitis B core antigen-positive results on serologic testing are a marker of high risk for hepatocellular carcinoma among patients with Hepatitis C virus-related cirrhosis."

"Interferon therapy might be less effective in preventing hepatocellular carcinoma among patients with chronic Hepatitis C who are anti-Hepatitis B core antigen-positive."

Ann Int Med 2007: 146(9): 649-56
03 May 2007

Go to top of page Email this page Email this page to a colleague

 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us